A human trial of Triticum aestivum L. sprout extract on improvement of muscle strength improvement

A 12 weeks, randomized, double-blind, placebo-controlled human trial to evaluate the efficacy and safety of Triticum aestivum L. sprout extract on muscle strength improvement

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0010794

Enrollment

100

Registered

2025-07-21

Start date

2023-06-30

Completion date

Unknown

Last updated

2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Dietary Supplement : • Triticum aestivum L. sprout extract group: 2 times a day, 2 capsules once, after breakfast/dinner, a duration of 12 weeks(1.6 g/day, Triticum aestivum L. sprout extract for 1 g

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Adult men and women aged 50 years or older and 85 years or less at the screening test 2) Subjects whose skeletal muscle mass measured by BIA(bioelectrical impedance analysis) is less than 110% 3) A person who, after hearing and fully understanding the detailed explanation of this trial, voluntarily decides to participate and agrees in writing to comply with the precautions

Exclusion criteria

Exclusion criteria: 1) Participants who are unable to participate in exercise programs 2) Participants who have continuously participated in aerobics or resistance exercise within 3 months prior to the screening visit 3) Participants with renal disease requiring treatment or whose serum creatinine is greater than 2.0 mg/dL 4) Participants with liver disease requiring treatment or those with AST(Aspartate Aminotransferase) or ALT(Alanine Aminotransferase) levels 3 times or more the upper limit of the reference range 5) uncontrolled diabetics{HbA1c(Hemoglobin A1C)>7.0%} 6) Participants with uncontrolled hypertension{SBP(Systolic Blood Pressure)>160 mmHg DBP(Diastolic Blood Pressure)>100 mmHg} 7) Participants who are unable to talk or walk due to dementia or Parkinson's disease 8) Participants with a history of significant hypersensitivity reactions to Wheat and wheat grass ingredients 9) Participants who have or are suspected of alcoholism or substance abuse 10) Participants who participated in other clinical trials within 3 months prior to screening 11) Pregnant or lactating women 12) Women of childbearing potential who do not accept the practice of adequate contraception 13) Participants who is judged unsuitable for participation in the study by the director of the study due to diagnostic test results and other reasons

Design outcomes

Primary

Measure	Time frame
isokinetic kinetic force;grip strength;Muscle mass	—

Secondary

Measure	Time frame
Physical function evaluation index;Calf circumference;SARC-F(STRENGTH, ASSISTANCE WITH WALKING, RISE FROM A CHAIR, CLIMB STAIRS AND FALLS);Muscle related hormones;Muscle related index;Inflammatory index;EQ-5D(EUROQOL-5 DIMENSIONS)	—

Countries

Korea, Republic of

Contacts

Public ContactYoon Sun Jung

Jeonbuk National University Hospital

sjyoon_kos@naver.com+82-63-250-1760

Outcome results